Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci098 in Graves' Disease
NCT07286656Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, single-arm trial of GenSci098 in Graves' disease, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Incidence and severity of adverse events (AEs) (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG]) at 141 days. Started Nov 2025; status: recruiting.
02
Drugs
GenSci098
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT07286656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286656.